WELCOME TO THE LAGANÀ LAB

Computational Cancer Genomics and Precision Oncology

RESEARCH

Computational Cancer Genomics and Precision Oncology

We develop computational methods and models that pull together genomic, transcriptomic, single-cell, and clinical data to track how multiple myeloma changes and reacts to therapy. The results help us chart tumor heterogeneity, find new drug targets, and give physicians AI-driven treatment options tailored to each patient.

Molecular Heterogeneity & Network Biology of Multiple Myeloma

Myeloma is not a single disease. We analyse whole-genome, RNA-seq and clinical data from thousands of patients, convert them into network models, and use those graphs to spot recurring genetic patterns. These molecular subtypes help doctors match risk level and therapy more accurately.

Learn More

Drivers of Progression, Resistance & High-Risk Disease

Relapse happens when therapy fails to clear the most resilient clones. We profile those clones at bulk, single-cell and spatial level to find the genetic events and pathways that drive resistance and rapid progression, with special focus on high-risk myeloma.

Learn More

Precision Oncology Platforms & AI-Enabled Decision Support

Sequencing data are useful only if clinicians can act on them. Our RADAR precision medicine platform turns WGS, WES and RNA-seq into an annotated PDF that supports clinical decision-making. A forthcoming AI layer, PROMETHEUS, will merge genomic results, patient records, and up-to-date literature into a dashboard that ranks therapy options and lets physicians explore each case in plain language.

Learn More

Micro-Environment, Immunotherapy & Digital Biomarkers

The success of CAR-T and bispecific antibodies depends on both the T cells and the bone-marrow environment. We profile immune subsets, cytokines and even wearable-device data to understand and predict treatment outcomes and toxicities.

Learn More

LAB MEMBERS

ALESSANDRO LAGANÀ, PHD

Principal Investigator

Alessandro Laganà is an Assistant Professor of Oncological Sciences and Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. His research interests lie primarily in the area of integrative cancer genomics, cancer network biology and precision oncology, with particular focus on Multiple Myeloma, a malignancy of bone marrow plasma cells.

Alessandro achieved his MS degree in Computer Science and PhD in Biology, Human Genetics and Bioinformatics at the University of Catania (Italy), under the supervision of Alfredo Ferro, and completed his Post-Doctoral studies in Carlo Croce's Lab at The Ohio State University in Columbus, OH, where his

research focused primarily on microRNA.

JUNIA VIEIRA DOS SANTOS, MD, PhD

Post-doctoral Fellow

Junia has completed her medical training and doctoral training in Universidade Federal do Ceará, Brazil and McGill University, Canada. Through her extensive training, she has continued to deepen her understanding of how medical genetics can be applied as a fundamental tool to direct translational studies into successful outcomes. With this goal, she completed McGill’s Clinical and Regulatory Affairs Fellowship and started a postdoctoral fellowship in Cancer Immunotherapy at Icahn School of Medicine at Mount Sinai. As a postdoctoral fellow, she is working with multidisciplinary teams under Dr. Alessandro Lagana and Dr. Samir Parekh's supervision on our mission to deliver exceptional care while conducting clinical trials with the most recent therapeutic options for Multiple Myeloma.

DAVID MELNEKOFF, PhD

Associate Computational Scientist

(Joint appointment with Samir Parekh's Lab)

David focuses on precision cancer medicine and clinical decision-making based on genomic sequencing. He received his B.S. from Columbia University in Biochemistry, and Ph.D. from the Icahn School of Medicine in Biomedical Sciences with a concentration in genetics and data science. David’s work focuses on using patient data for a variety of clinical and research studies, including clinical trial data analysis and analysis of wet-lab and genomic sequencing data. David’s most recent work has been the analysis of single-cell sequencing data of patients receiving novel immune therapies, including Chimeric Antigen T Cell (CAR T) and Bi-specific Antibodies, for the treatment of Multiple Myeloma. David also has a special interest in the study and implementation of Intra-Tumor Heterogeneity estimates as it relates to patient treatment and outcomes, by using next-generation sequencing data of patient tumor samples to provide alternative and complimentary drug recommendations.

MUJAHID ALI QUIDWAI, MSc

Associate Computational Scientist

Mujahid (Ali)'s work lies at the intersection of AI, biomedical informatics, and clinical genomics—driving innovations that transform unstructured scientific literature and patient data into actionable insights.
He architected OncoDIF, an AI-powered framework for precision oncology, combining RAG pipelines, ReAct agents, and large language models to surface clinically relevant insights from genomic data. He has also investigated the use of machine learning for monitoring CAR-T therapy- related toxicities and is leading the development of a multimodal patient platform integrating EHRs, lab data, and advanced foundation models like Geneformer and Mistral.
Previously a TA and graduate researcher at NYU, he is passionate about building tools that make complex science more accessible—for researchers, clinicians, and patients alike.

ALESSIA D'ANNA, PhD

Post-doctoral Fellow

Alessia's research focuses on bioinformatics approaches for the study of multiple myeloma, with an emphasis on precision oncology and the integration of high-throughput molecular data. She is particularly interested in identifying novel drivers of high-risk disease, understanding inter- and intra-tumor heterogeneity, and defining key determinants of response to targeted therapies and immunotherapies. Her work involves the development and application of computational tools for the analysis of bulk and single-cell DNA and RNA sequencing data.
She holds an MSc in Medical Physics and earned her PhD in Complex Systems for Physical, Socio-Economic, and Life Sciences from the University of Catania in 2024. During her PhD, she gained hands-on experience in clinical imaging and radiomics, and worked across transcriptomics and genomics to develop integrative strategies for personalized cancer treatment.

ALISON PARK, MSc

Bioinformatician I

With a background in biomedical science, Alison's projects are focused on multi-omic data integration and analysis. Her work is centered on discovering novel therapeutic approaches for multiple myeloma patients by leveraging patient networks and advancing precision medicine. Alison is also deeply committed to harnessing the power of machine learning and artificial intelligence to drive breakthroughs in cancer biology and accelerate the discovery of innovative treatment approaches.
Outside of work, she enjoys nature walks, playing golf, as well as diving into a good book during her spare time.

MEGHANA RAM, MSc

Associate Researcher II

Meghana received her master’s degree in Individualized Genomics and Health from Johns Hopkins University. She plans to pursue a PhD. in the future, with an intent to have a career in academia. In her spare time, she enjoys reading, cooking, dancing Kathak (Indian classical dance form) and learning new languages.

PEER-REVIEWED PUBLICATIONS

M. Ram M, M. R. Fraser, J. Vieira Dos Santos, R. Tasakis, A. Islam, J. U. Abo-Donia, S. Parekh, A. Laganà. The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward. Pharm Genomics Pers Med 2024 Dec 21; 17:573-609. doi: 10.2147/PGPM.S350238. eCollection 2024.

R. P. Dutta, S. Thibaud, V. Leshchenko, M. Ram, D. T. Melnekoff, S. Bhalla, P. Restrepo, V. A. Gupta, B. G. Barwick, S. Newman, J. McCafferty, F. Hantash, A. K. Nooka, H. J. Cho, S. Richard, C. Rodriguez, A. Rossi, L. Sanchez, A. Chari, L. H. Boise, S. Jagannath, J. Richter, S. Parekh, A. Laganà. Predictors of Response to Venetoclax and Therapeutic Potential of CDK7 Inhibition in Multiple Myeloma. To appear in Blood Neoplasia 2024.

S. Bodnar, T. Brander, J. Gold, A. Iverson, A. Laganà, K. Onel, S. Jagannath, S. Parekh, S. Thibaud. FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk. Semin Hematol 2024 Nov 30: S0037-1963(24)00131-8. doi: 10.1053/j.seminhematol.2024.11.006.

A. H. Mei, A. Laganà, R. Osman, H. J. Cho. Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma. Semin Hematol 2024 Oct 28: S0037-1963(24)00124-0. doi:10.1053/j.seminhematol.2024.10.007.

Z. M. Avigan, C. S. Mitsiades, A. Laganà. The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges. Semin Hematol 2024; Oct 5: S0037-1963(24)00111-2. doi: 10.1053/j.seminhematol.2024.10.001.

S. Thibaud, R. L. Subaran , S. Newman, A. Laganà, D. T. Melnekoff, S. Bodnar, M. Ram, Z. Soens, W. Genthe, T. Brander, T. H. Mouhieddine, O. Van Oekelen, J. Houldsworth, H. J. Cho, S. Richard, J. Richter, C. Rodriguez, A. Rossi, L. Sanchez, A. Chari, E. Moshier, S. Jagannath, S. Parekh, K. Onel. Multiple Myeloma Risk and Outcomes are Associated with Pathogenic Germline Variants in DNA Repair Genes. Blood Cancer Discov 2024. doi: 10.1158/2643-3230.BCD-23-0208.

O. Van Oekelen, M. Amatangelo, M. Guo, B. Upadhyaya, A. P. Cribbs, G. Kelly, M. Patel, S. Kim-Schulze, E. Flynt, A. Laganà, S. Gooding, M. Merad, S. Jagganath, W. E. Pierceall, U. Oppermann, A. Thakurta, S. Parekh. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma. Cell Rep Med 2024 Jun 18;5(6):101584. doi:10.1016/j.xcrm.2024.101584.

T. H. Mouhieddine, O. Van Oekelen, D. T. Melnekoff, J. Li, Y. Ghodke-Puranik, G. Lancman, S. Thibaud, D. Pan, S. Rajeeve, S. Agte, A. Aleman, L. Sanchez, S. Richard, A. Rossi, J. Richter, H. J. Cho, C. Rodriguez, A. Laganà, E. L. Moshier, A. Chari, S. Jagannath, S. Parekh. Sequencing T-cell redirection therapies leads to deep and durable responses in relapsed/refractory myeloma patients. Blood Adv. 2023; 7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923.

R. Distefano, L. Tomasello, G. L. Rampioni Vinciguerra, P. Gasparini, Y. Xiang, M. Bagnoli, G. P. Marceca, P. Fadda, A. Laganà, M. Acunzo, Q. Ma, G. Nigita, C. M. Croce. Pan-Cancer Analysis of Canonical and Modified miRNAs Enhances the Resolution of the Functional miRNAome in Cancer. Cancer Res. 2022; 82(20): 3687–3700.

M. Elnaggar, S. Agte, P. Restrepo, M. Ram, D. Melnekoff, C. Adamopoulos, M. M. Stevens, K. Kappes, V. Leshchenko, D. Verina, S. Jagannath, P. I. Poulikakos, S. Parekh, A. Laganà. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation. J Hematol Oncol. 2022; 15(1):109. doi: 10.1186/s13045-022-01330-3.

P. Restrepo, S. Bhalla, Y. Ghodke-Puranik, A. Aleman, V. Leshchenko, D. T. Melnekoff, S. Agte, J. Jiang, D. Madduri, J. Richter, S. Richard, A. Chari, H. J. Cho, S. Jagannath, C. J. Walker, Y. Landesman, A. Laganà, S. Parekh. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precis Oncol. 2022; 6:e2200147. doi: 10.1200/PO.22.00147.

O. Van Oekelen, A. Aleman, B. Upadhyaya, S. Schnakenberg, D. Madduri, S. Gavane, J. Teruya-Feldstein, J. F. Crary, M. E. Fowkes, C. B. Stacy, S. Kim-Schulze, A. Rahman, A. Laganà, J. D. Brody, M. Merad, S. Jagannath, S. Parekh. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine 2021; https://doi.org/10.1038/s41591-021-01564-7.
S. Bhalla, D. T. Melnekoff, A. Aleman, V. Leshchenko, P. Restrepo, J. Keats, K. Onel, J. R. Sawyer, D. Madduri, J. Richter, S. Richard, A. Chari, H. J. Cho, J. T. Dudley, S. Jagannath, A. Laganà, S. Parekh. Patient Similarity Network of Multiple Myeloma identifies patient sub-groups with distinct genetic and clinical features. Science Advances 2021; 7(47). doi:10.1126/sciadv.abg9551.

S. S. Jatiani, S. Christie, V. V. Leshchenko, R. Jain, A. Kapoor, P. Bisignano, C. Lee, H. Ü. Kaniskan, D. Edwards, F. Meng, A. Laganà, Y. Youssef, A. Wiestner, L. Alinari, J. Jin, M. Filizola, A. K. Aggarwal, S. Parekh. SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. Clin Cancer Res 2021; 27(16):4652-4663. doi: 10.1158/1078-0432.CCR-20-5039.

G. P. Marceca, R. Distefano, L. Tomasello, A. Laganà, F. Russo, F. Calore, G. Romano, M. Bagnoli, P. Gasparini, A. Ferro, M. Acunzo, Q. Ma, C. M. Croce, G. Nigita. MiREDiBase, a manually curated database of validated and putative editing events in microRNAs. Scientific Data 2021; 8:199. doi: https://doi.org/10.1038/s41597-021-00979-8

A. Chari, E. Florendo, I. S. Mancia, H. Cho, D. Madduri, S. Parekh, J. Richter, A. Dhadwal, J. Thomas, G. Jiang, A. Laganà, S. Bhalla, S. Jagannath. Optimal Supportive Care with Selinexor Improves Outcomes in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia 2021; doi: https://doi.org/10.1016/j.clml.2021.07.014.

R. Upadhyay, J. A. Boiarsky, G. Pantsulaia, J. Svensson-Arvelund, M. J. Lin, A. Wroblewska, S. Bhalla, N. Scholler, A. Bot, J. M. Rossi, N. Sadek, S. Parekh, A. Laganà, A. Baccarini, M. Merad, B. D. Brown, J. D. Brody. A critical role for fas-mediated off-target tumor killing in T cell immunotherapy. Cancer Discovery 2020; doi: 10.1158/2159-8290.CD-20-0756.

M. R. Sapienza, F. Fuligni, F. Melle, V. Tabanelli, V. Indio, M. A. Laginestra, G. Motta, S. Mazzara, L. Cerroni, A. Pileri, F. Facchetti, M. Paulli, L. Cascione, A. Laganà, E. Berti, C. Agostinelli, E. Sabattini, C. M. Croce, S. A. Pileri. MicroRNA profiling of Blastic Plasmacytoid Dendritic Cell Neoplasm and Myeloid Sarcoma. Hematological Oncology 2020; doi: https://doi.org/10.1002/hon.2782.

O. Van Oekelen, S. Parekh, H. J. Cho, N. Vishnuvardhan, D. Madduri, J. Richter, C. Ip, K. Lau, E. Florendo, I. S. Mancia, J. Thomas, D. Verina, E. Chan, K. Zarychta, L. La, G. Strumolo, D. T. Melnekoff, V. V. Leshchenko, S. Kim-Schulze, S. Cuoto, M. Wang, W. E. Pierceall, A. Thakurta, A. Laganà, S. Jagannath, A. Chari. A Phase II Study of Pomalidomide, Daily Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Leukemia & Lymphoma 2020; doi: 10.1080/10428194.2020.1805111.

A. Ma, E. Stratikopoulos, K.S. Park, J. Wei, T. C. Martin, X. Yang, M. Schwarz, V. Leshchenko, A. Rialdi, B. Dale, A. Laganà, E. Guccione, S. Parekh, R. Parsons, J. Jin. Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology 2020; 16(2):214-222. doi: 10.1038/s41589-019-0421-4.

D. Perumal, N. Imai, A. Laganà, J. P. Finnigan, D. T. Melnekoff, V. Leshchenko, A. Solovyov, D. Madduri, S. Kim-Schulze, A. Chari, H. J. Cho, J. T. Dudley, J. Brody, B. Barlogie, S. Jagannath, B. Greenbaum, S. Gnjatic, N. Bhardwaj, S. Parekh. Patient-Specific Mutation-Derived Tumor Antigens as Targets for Cancer Immunotherapy in Multiple Myeloma. Clinical Cancer Research 2020; 15;26(2):450-464. doi: 10.1158/1078-0432.CCR-19-2309.

Y. Liu, H. Yu, S. Yoo, E. Lee, A. Laganà, S. Parekh, E. E. Schadt, L. Wang, J. Zhu. A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers (Basel) 2019; 11(10). pii: E1452. doi: 10.3390/cancers11101452.

A. Laganà, I. Beno, D. Melnekoff, V. Leshchenko, D. Madduri, D. Ramdas, L. Sanchez, S. Niglio, D. Perumal, B. A. Kidd, R. Miotto, J. Houldsworth, R. Shaknovich, A. Chari, H. J. Cho, B. Barlogie, S. Jagannath, J. T. Dudley, S. Parekh. Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precision Oncology 2018. doi: 10.1200/PO.18.00019.

L. Shi, J. Middleton, Y. J. Jeon, P. Magee, D. Veneziano, A. Laganà, H. S. Leong, S. Sahoo, M. Fassan, R. Booton, R. Shah, P. A. J. Crosbie, M. Garofalo. KRAS induces lung tumorigenesis through microRNAs modulation. Cell Death Dis 2018; 13;9(2):219. doi: 10.1038/s41419-017-0243-9.

S. Naidu, L. Shi, P. Magee, J. D. Middleton, A. Laganà, S. Sahoo, H. S. Leong, M. Galvin, K. Frese, C. Dive, V. Guzzardo, M. Fassan, M. Garofalo. PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways. Scientific Reports 2017; doi:10.1038/s41598-017-14843-6.

F. Russo, S. Di Bella, F. Vannini, G. Berti, F. Scoyni, H. V. Cook, A. Santos, G. Nigita, V. Bonnici, A. Laganà, F. Geraci, A. Pulvirenti, R. Giugno, F. De Masi, K. Belling, L. J. Jensen, S. Brunak, M. Pellegrini, A. Ferro. miRandola 2017: a curated knowledge base of non-invasive biomarkers. Nucleic Acids Res 2017; gkx854, https://doi.org/10.1093/nar/gkx854.

A. Chari, H. J. Cho, A. Dhadwal, G. Morgan, L. La, K. Zarychta, D. Catamero, E. Florendo, N. Stevens, D. Verina, E. Chan, V. Leshchenko, A. Laganà, D. Perumal, A. H. Mei, K. Tung, J. Fukui, S. Jagannath, S. Parekh. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances 2017; doi:10.1182/bloodadvances.2017007427.

A. Laganà, W. P. Dirksen, W. Supsavhad, A. S. Yilmaz, H. G. Ozer, J. D. Feller, K. A. Vala, C. M. Croce, T. J. Rosol. Discovery and characterization of the feline miRNAome. Scientific Reports 2017; doi:10.1038/s41598-017-10164-w.

A. Laganà, D. Perumal, D. Melnekoff, B. Readhead, B. A. Kidd, V. Leshchenko, P.-Y. Kuo, J. Keats, M. DeRome, J. Yesil, D. Auclair, S. Lonial, A. Chari, H. J. Cho, B. Barlogie, S. Jagannath, J. T. Dudley, S. Parekh. Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma. Leukemia 2017; doi: 10.1038/leu.2017.197.

M. Acunzo, G. Romano, G. Nigita, D. Veneziano, L. Fattore, A. Laganà, N. Zanesi, P. Fadda, M. Fassan, L. Rizzotto, R. Kladney, V. Coppola, C. M. Croce. Selective targeting of point-mutated KRAS through artificial microRNAs. Proc Natl Acad Sci U S A 2017; doi: 10.1073/pnas.1620562114.

D. Veneziano, S. Di Bella, G. Nigita, A. Laganà, A. Ferro, C. M. Croce. Non-coding RNA: Current Deep Sequencing Data Analysis Approaches and Challenges. Human Mutation 2016; 37 (12) 1283-1298.

L. Fattore, R. Mancini, M. Acunzo, G. Romano, A. Laganà, M. E. Pisanue, D. Malpiccie, G. Madonna, D. Mallardo, M. Capone, F. Fulciniti, L. Mazzucchelli, G. Botti, C. M. Croce, P. A. Ascierto, G. Ciliberto. miR-579-3p controls melanoma progression and resistance to target therapy. Proc Natl Acad Sci U S A 2016; 113(34):E5005-13. doi: 10.1073/pnas.1607753113.

G. Nigita, M. Acunzo, G. Romano, D. Veneziano, A. Laganà, M. Vitiello, D. Wernicke, A. Ferro, C. M. Croce. microRNA editing in seed region aligns with cellular changes in hypoxic conditions. Nucleic Acids Res 2016; doi: 10.1093/nar/gkw532.

A. Laganà, D. Veneziano, T. Spata, R. Tang, H. Zhu, P. J. Mohler, A. Kilic. Identification of General and Heart-Specific miRNAs in Sheep (Ovis aries). PLOS ONE 2015; doi: 10.1371/jour- nal.pone.0143313.

A. Laganà, A. Ferro, C. M. Croce. Editorial: Bioinformatics of Non-Coding RNAs with Applications to Biomedicine: Recent Advances and Open Challenges. Front. Bioeng. Biotechnol. 2015; 3:156. doi: 10.3389/fbioe.2015.00156.

E. Tili, M. Chiabai, D. Palmieri, M. Brown, R. Cui, C. Fernandes, T. Richmond, T. Kim, T. Sheetz, H. L. Sun, A. Laganà, D. Veneziano, S. Volinia, L. Rassenti, T. Kipps, H. Awad, J. J. Michaille, C. M. Croce. Quaking and miR-155 interactions in inflammation and leukemogenesis. Oncotarget 2015.

P. Joshi P, Y. J. Jeon, A. Laganà, J. Middleton, P. Secchiero, M. Garofalo, C. M. Croce. MicroRNA- 148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci U S A 2015; 112(28):8650-5.

Y. J. Jeon, J. Middleton, T. Kim, A. Laganà, C. Piovan, P. Secchiero, G. J. Nuovo, R. Cui, P. Joshi, G. Romano, G. Di Leva, B. K. Lee, H. L. Sun, Y. Kim, P. Fadda, H. Alder, M. Garofalo, C. M. Croce. A set of NF-kB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer. Proc Natl Acad Sci U S A 2015; 112(26):E3355-64.

A. Drusco, A. Bottoni, A. Laganà, M. Acunzo, M. Fassan, L. Cascione, A. Antenucci, P. Kumchala, C. Vicentini, M. P. Gardinam, H. Alder, M. A. Carosi, M. Ammirati, S. Gherardi, M. Luscrì, C. Carapella, N. Zanesi, C. M. Croce. A differentially expressed set of micrornas in cerebro-spinal fluid (CSF) can diagnose CNS malignancies. Oncotarget 2015.

C. Tibaldi, A. D’Incecco, A. Laganà. MicroRNAs and Targeted Therapies in Non-Small Cell Lung Cancer: Minireview. Anticancer Agents Med Chem 2015.

A. Laganà, D. Shasha, C. M. Croce. Synthetic RNAs for gene regulation: design principles and computational tools. Front Bioeng Biotechnol 2014; 2:65. doi: 10.3389/fbioe.2014.00065.

S. V. Thomas, A. Laganà, K. M. Dittmar, P. E. Wakely Jr. Imprint cytopathology of core needle biopsies: a first responder role for cytotechnologists. Journal of the American Society of Cytopathology 2014; 4(1): 16-24.

A. Efanov, N. Zanesi, V. Coppola, G. Nuovo, B. Bolon, D. Wernicke-Jameson, A. Laganà, H. Alder, F. Pichiorri and C. M. Croce. Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia. Blood Cancer J 2014; 4:e227.

F. Russo, S. Di Bella, V. Bonnici, A. Laganà, G. Rainaldi, M. Pellegrini, A. Pulvirenti, R. Giugno, A. Ferro. A knowledge base for the discovery of function, diagnostic potential and drug effects on cellular and extracellular miRNAs. BMC Genomics 2014; 15(Suppl 3):S4.

A. Laganà, M. Acunzo, G. Romano, A. Pulvirenti, D. Veneziano, L. Cascione, R. Giugno, P. Gasparini, D. Shasha, A. Ferro, C. M. Croce. miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. Nucleic Acids Res 2014; doi:10.1093/nar/gku202.

P. Nasarre, R. M. Gemmill, V. A. Potiron, J. Roche, X. Lu, A. E. Baron, C. Korch, E. Garrett-Mayer, A. Laganà, P. H. Howe, H. A. Drabkin. Neuropilin-2 is upregulated in lung cancer cells during TGF1-induced epithelialmesenchymal transition. Cancer Res 2013; 73(23):7111-7121.

A. Laganà, F. Russo, D. Veneziano, S. Di Bella, A. Pulvirenti, R. Giugno, C. M. Croce, A. Ferro. Extracellular circulating viral microRNAs: current knowledge and perspectives. Frontiers in Genetics 2013; 4:120.

M. Acunzo, G. Romano, D. Palmieri, A. Laganà, M. Garofalo, V. Balatti, A. Drusco, M. Chiariello, P. Nana-Sinkam, C. M. Croce. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A 2013; 110(21):8573-8578.

F. Pichiorri, D. Palmieri, L. De Luca, J. Consiglio, J. You, A. Rocci, T. Talabere, C. Piovan, A. Laganà, L. Cascione, J. Guan, P. Gasparini, V. Balatti, G. Nuovo, V. Coppola, C. C. Hofmeister, G. Marcucci, J. C. Byrd, S. Volinia, C. L. Shapiro, M. A. Freitas, C. M. Croce. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2013; 210(5):951-68.

N. Zanesi, V. Balatti, J. Riordan, A. Burch, L. Rizzotto, A. Palamarchuk, L. Cascione, A. Laganà, A. J. Dupuy, C. M. Croce, Y. Pekarsky. A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model. Blood 2013; 121(21):4355-4358.

V. Manfè, E. Biskup, A. Willumsgaard, A. G. Skov, D. Palmieri, P. Gasparini, A. Laganà, A. Woet- mann, N. Odum, C. M. Croce, R. Gniadecki. cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. PLoS ONE 2013; 8(3): e59390.

R. Distefano, G. Nigita, V. Macca, A. Laganà, R. Giugno, A. Pulvirenti, A. Ferro. VIRGO: visualization of A-to-I RNA editing sites in genomic sequences. BMC Bioinformatics 2013; 14(Suppl 7): S5.

F. Russo, S. Di Bella, G. Nigita, V. Macca, A. Laganà, R. Giugno, A. Pulvirenti, A. Ferro. miRandola: Extracellular Circulating MicroRNAs Database. PLoS ONE 2012; 7(10): e47786.

A. Laganà, A. Paone, D. Veneziano, L. Cascione, P. Gasparini, S. Carasi, F. Russo, G. Nigita, V. Macca, R. Giugno, A. Pulvirenti, D. Shasha, A. Ferro, C. M. Croce. miR-EdiTar: A database of predicted A-to-I edited miRNA target sites. Bioinformatics 2012; 28(23): 3166-3168.

P. Ranganathan, C. E. Heaphy, S. Costinean, N. Stauffer, C. Na, M. Hamadani, R. Santhanam, C. Mao, P. A. Taylor, S. Sandhu, G. He, A. Shana’ah, G. J. Nuovo, A. Laganà, L. Cascione, S. Obad, O. Broom, S. Kauppinen, J. C. Byrd, M. Caligiuri, D. Perrotti, G. A. Hadley, G. Marcucci, S. M. Devine, B. R. Blazar, C. M. Croce, R. Garzon. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012; 119(20): 4786-4797.

A. Laganà, F. Russo, C. Sismeiro, R. Giugno, A. Pulvirenti, A. Ferro. Variability in the Incidence of miRNAs and Genes in Fragile Sites and the Role of Repeats and CpG Islands in the Distribution of Genetic Material. PLoS ONE 2010; 5(6): e11166.

A. Laganà, S. Forte, F. Russo, R. Giugno, A. Pulvirenti, A. Ferro. Prediction of human targets for viral-encoded microRNAs by thermodynamics and empirical constraints. Journal of RNAi and Gene Silencing 2010; 6(1): 379-385.

A. Laganà, S. Forte, A. Giudice, M. R. Arena, P. L. Puglisi, R. Giugno, A. Pulvirenti, D. Shasha, A. Ferro. miRò: a miRNA knowledge base. Database 2009; Vol. 2009, bap008.

V. Svicher, C. Alteri, R. DArrigo, A. Laganà, M. Trignetti, S. Lo Caputo, A. P. Callegaro, F. Maggiolo, F. Mazzotta, A. Ferro, S. Dimonte, S. Aquaro, G. di Perri, S. Bonora, C. Tommasi, M. P. Trotta, P. Narciso, A. Antinori, C. F. Perno, F. Ceccherini-Silberstein. The Treatment with the Fusion Inhibitor Enfuvirtide Influences the Appearance of Mutations in the HIV-1 Regulatory Protein Rev. Antimicrobial Agents and Chemotherapy 2009; 53(7): 2816-2823.

C. Di Pietro, M. Ragusa, D. Barbagallo, L. R. Duro, M. R. Guglielmino, A. Majorana V. Giunta, A. Rapisarda, E. Tricarichi, M. Miceli, R. Angelica, A. Grillo, B. Banelli, I. Defferari, S. Forte, A. Laganà, C. Bosco, R. Giugno, A. Pulvirenti, A. Ferro, K. H. Grzeschik, A. Di Cataldo,G. P. Tonini, M. Romani, M. Purrello. Involvement of GTA protein NC2beta in Neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation. Molecular Cancer 2008; 7:52.

C. Di Pietro, M. Ragusa, L. Duro, M. R. Guglielmino, D. Barbagallo, A. Carnemolla, A. Laganà, P. Buffa, R. Angelica, A. Rinaldi, M. S. Calafato, I. Milicia, C. Caserta, R. Giugno, A. Pulvirenti, V. Giunta, A. Rapisarda, V. Di Pietro, A. Grillo, A. Messina, A. Ferro, K. H. Grzeschik, M. Purrello. Genomics, Evolution and Expression of TBPL2, a Member of the TBP Family. DNA and Cell Biology 2007; 26(6): 369-385.

CONTACT US

Icahn School of Medicine at Mount Sinai

Department of Oncological Sciences

Department of Genetics and Genomic Sciences

Tisch Cancer Institute

1470 Madison Avenue New York NY 10029

alessandro.lagana@mssm.edu